利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.02 秒)

    COMBINATION THERAPY TO TREAT SICKLE CELL DISEASE AND RESTORE RBC FUNCTIONS
    4.
    发明公开
    COMBINATION THERAPY TO TREAT SICKLE CELL DISEASE AND RESTORE RBC FUNCTIONS 审中-公开
    联合治疗治疗镰状细胞病和恢复RBC功能

    公开(公告)号：EP3275458A1

    公开(公告)日：2018-01-31

    申请号：EP16181521.2

    申请日：2016-07-27

    申请人： Hartis-Pharma Sarl

    发明人： Joseph Eric, Niesor ,  Renée, Benghozi ,  François, Lamour

    IPC分类号： A61K38/00 ,  A61K31/00 ,  A61P7/06

    CPC分类号： C12Y203/01043 ,  A61K31/07 ,  A61K31/216 ,  A61K31/355 ,  A61K31/4439 ,  A61K31/455 ,  A61K38/1709 ,  A61K38/45 ,  A61K2300/00

    摘要： Disclosed is a new combination therapy to treat sickle cell disease (SCD) and thalassemia and their vascular acute and chronic complications by a therapy involving the combined administration of a compound improving HDL particle function and activity (i.e. increasing HDL/ ApoA1 levels), and liposoluble antioxidants xanthophylls (such as lutein, zeaxanthin, meso-zeaxanthin, astaxanthin). This method simultaneously and synergistically restores red blood cell function, normalizes red blood cell membrane cholesterol concentration and decreases oxidative stress both parameters being pathologically affected in SCD, thalassemia and diabetes secondary to low levels of plasma HDL and decreased absorption of dietary lipophilic antioxidant.
    Although it is known that HDL is involved in the selective and active intestinal uptake of liposoluble vitamins and antioxidants and that HDL uniquely removes excess membrane cholesterol from red blood cells, we discovered that the combination of an HDL therapeutic intervention together with a dietary supplement (as a free or fixed combination) of liposoluble antioxidants act synergistically for treating the rheological complications of sickle cell disease as well as thalassemia and subsequently will contribute to treating and preventing microvascular damages and associated pathologies (retinopathies, kidney failure, leg ulcer, priapism, acute chest syndrome, stroke etc.). Similarly Diabetes, which includes hemorheological abnormalities associated with high red blood cell membrane cholesterol and low plasma HDL antioxidant level will benefit from such combinations. Additional compounds affecting HDL are ApoA1 inducers, HDL and ApoA1 mimetics or (mimicking compounds) ApoA1 and ApoE analogues, Lecithin Cholesterol Acyl Transferase (LCAT) activators, CETP inhibitors and modulators, Peroxisome Proliferator Activated Receptor (PPAR) agonists, ATP Binding Cassette A1 (ABCA1) inducers, Niacin and analogues, Niacin Receptor agonists. Additional lipophilic antioxidants are tocopherols and tocotrienols.

    摘要翻译： 本发明公开了一种通过联合给药改善HDL颗粒功能和活性的化合物（即增加HDL / ApoA1水平）和脂溶性治疗来治疗镰状细胞病（SCD）和地中海贫血及其血管急性和慢性并发症的新型组合疗法 抗氧化剂叶黄素（如叶黄素，玉米黄素，内消旋 - 玉米黄质，虾青素）。 该方法同时并协同恢复红细胞功能，使红细胞膜胆固醇浓度正常化并降低氧化应激，这两个参数在SCD，地中海贫血和糖尿病中均受到病理影响，继发于低水平的血浆HDL和降低的膳食亲脂性抗氧化剂的吸收。 虽然已知HDL参与了脂溶性维生素和抗氧化剂的选择性和主动吸收肠内脂质，并且HDL独特地从红细胞中去除了过量的膜胆固醇，但我们发现HDL治疗性干预与膳食补充剂（作为 游离或固定组合）脂溶性抗氧化剂协同作用治疗镰状细胞病以及地中海贫血的流变学并发症，并且随后将有助于治疗和预防微血管损伤和相关病状（视网膜病，肾衰竭，腿部溃疡，阴茎异常勃起，急性胸部 综合征，中风等）。 类似地，包括与高红细胞膜胆固醇和低血浆HDL抗氧化剂水平相关的血液流变学异常的糖尿病将受益于这样的组合。 影响HDL的其他化合物是ApoA1诱导剂，HDL和ApoA1模拟物或（模拟化合物）ApoA1和ApoE类似物，卵磷脂胆固醇酰基转移酶（LCAT）激活剂，CETP抑制剂和调节剂，过氧化物酶体增殖物激活受体（PPAR）激动剂，ATP结合盒A1 ABCA1）诱导剂，烟酸和类似物，烟酸受体激动剂。 另外的亲脂性抗氧化剂是生育酚和生育三烯酚。

    METHOD
    6.
    发明公开
    METHOD 有权
    方法ZUR HERSTELLUNG VON MILCHPULVER

    公开(公告)号：EP2501242A1

    公开(公告)日：2012-09-26

    申请号：EP10784586.9

    申请日：2010-11-08

    申请人： DuPont Nutrition Biosciences ApS

    发明人： LARSEN, Niels Erik ,  SØE, Jørn Borch

    IPC分类号： A23C9/18 ,  C12N9/10

    CPC分类号： A23C9/1216 ,  C07K14/71 ,  C12Y203/01043

    摘要： A method of producing powder milk, said method comprising: (a) contacting milk or a fraction thereof with a lipid acyltransferase enzyme; and (b) drying the enzyme treated milk to produce powder milk; is disclosed. Powder milk products produced by the method and use of a lipid acyltransferase in the manufacture of powder milk for improving the rehydration properties, the perceptible sensory difference (smell and/or taste) and the flowability of the powder milk, and for reducing the cholesterol content and/or the free fatty acid content of the powder milk, and for reducing fouling of the equipment used in the manufacture of the powder milk, are also disclosed.

    摘要翻译： 一种生产粉末乳的方法，所述方法包括：（a）使乳或其一部分与脂质酰基转移酶接触; 和（b）干燥酶处理的牛奶以产生粉末奶; 被披露。 通过脂质酰基转移酶的方法生产的粉末奶制品，用于制造粉末乳，用于改善补液性能，可感知的感觉差异（气味和/或味道）和粉末奶的流动性以及降低胆固醇含量 和/或粉末奶的游离脂肪酸含量，以及用于减少用于制造粉末奶的设备的结垢。